PFE · 10-Q · 2026Q3

PFIZER INC

Filed 2026-11-03 · Healthcare · View original filing on EDGAR

Ranked Events

• Intangible Asset ImpairmentsImportance 69 · Surprise 64
  For the nine months ended September 27, 2026, Pfizer’s reconciliation included a $4.325 billion adjustment for certain asset impairments. The comparable 2025 nine-month reconciliation showed a $577 million adjustment…
• Operating Cash Flow TrendsImportance 64 · Surprise 56
  Operating cash flow for the nine months ended September 27, 2026 increased to $8.825 billion from $6.356 billion in the prior-year period, a 39% increase. Pfizer attributed the increase mainly to the timing of…
• Litigation and Legal RiskImportance 58 · Surprise 56
  For the first nine months of 2026, Pfizer recorded $1.0 billion of charges for certain legal matters, primarily product liability and other legal expenses. The comparable charges for the first nine months of 2025 were…
• Manufacturing Footprint OptimizationImportance 58 · Surprise 42
  In the third quarter of 2026, Pfizer announced a new phase of its Manufacturing Optimization Program, focused on network structure changes, product portfolio enhancements and operational efficiencies. The phase is…
• Restructuring ChargesImportance 58 · Surprise 42
  Pfizer announced an additional $1.0 billion of anticipated net savings from its Realigning Our Cost Base Program, bringing expected cumulative savings to approximately $6.7 billion through 2029; the additional savings…
• Revenue Performance and MixImportance 57 · Surprise 64
  Third-quarter revenue was relatively flat, while revenue excluding Comirnaty and Paxlovid increased 7% operationally; nine-month revenue also increased 7% excluding those COVID-19 products. Demand and market-share…
• Trade Policy and TariffsImportance 53 · Surprise 60
  On April 2, 2026, the U.S. Government announced Section 232 tariffs of up to 100% on imported patented pharmaceuticals and their ingredients, citing national-security concerns about supply-chain reliance. The measures,…
• Metsera Acquisition SynergiesImportance 52 · Surprise 42
  Following the November 2025 acquisition of Metsera, Pfizer expects approximately $600 million in annual cost synergies by the end of 2026. The one-time costs to generate those synergies are expected to total…
• ViiV Investment ExitImportance 48 · Surprise 42
  Pfizer completed the sale of its 11.7% investment in ViiV on March 31, 2026, during its second fiscal quarter. The transaction generated $1.875 billion in cash proceeds. The sale contributed to a $1.870 billion net…
• Drug Pricing PolicyImportance 46 · Surprise 42
  Pfizer expects continued U.S. government and state attention to drug pricing and access, including international reference pricing and Most-Favored-Nation pricing. Under the Inflation Reduction Act’s Medicare Drug…
• Product Pipeline ProgressImportance 41 · Surprise 42
  Pfizer reported 2026 U.S. approval of Veppanu (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer and U.S. and EU approvals expanding Padcev and other products into additional treatment…
• Acquired In-Process R&D ExpenseImportance 34 · Surprise 42
  Acquired in-process research and development expense declined $722 million in the third quarter and $579 million in the first nine months of 2026. The 2026 expense included a $650 million charge for an in-licensing and…
• Research and Development ExpenseImportance 32 · Surprise 24
  Research and development expense increased $469 million in the third quarter and $1.1 billion in the first nine months of 2026. Spending on certain oncology and obesity candidates rose $230 million in the quarter and…
• Capital Allocation StrategyImportance 26 · Surprise 24
  Pfizer’s capital allocation framework prioritizes reinvestment in the business, maintaining and over the long term growing its dividend, and potentially resuming share repurchases after de-leveraging. The company…
• Share Repurchase ProgramImportance 26 · Surprise 24
  Pfizer had $3.3 billion remaining under its share-purchase authorization as of September 27, 2026. The company made no share repurchases in the first nine months of 2026. Pfizer’s capital allocation framework says…
• OECD Global Minimum TaxImportance 26 · Surprise 24
  Countries outside the U.S. have enacted global minimum tax legislation under the OECD’s Base Erosion and Profit Shifting Pillar Two project, with provisions generally effective for Pfizer since 2024. The company says…
• Liquidity and Debt PositionImportance 25 · Surprise 6
  Pfizer reported access to a $7.0 billion committed revolving credit facility maturing in October 2031 and an additional $220 million of lender-provided lines of credit. All credit lines were unused as of the filing…
• Net Income and ProfitabilityImportance 24 · Surprise 14
  Income from continuing operations before taxes increased $51 million to $3.4 billion in the third quarter of 2026 from $3.3 billion a year earlier. The quarterly comparison benefited from lower cost of sales and…
• Other Income and ImpairmentsImportance 23 · Surprise 6
  Other income and deductions showed a favorable $229 million period-over-period change in the third quarter, reflecting the non-recurrence of a prior-year intangible impairment, lower legal charges, higher…
• Operating Expense TrendsImportance 18 · Surprise 14
  Selling, informational and administrative expenses rose $93 million in the third quarter to $3.279 billion, including $100 million higher compensation costs, $40 million from a lower favorable U.S. healthcare reform…

Revenue by Product (in millions)

Revenue by Geography (in millions)